SPARC secures Priority Review Voucher associated with Sezaby approval

03 Feb 2026 Evaluate

Sun Pharma Advanced Research Company (SPARC) has secured a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby from United States Food and Drug Administration (USFDA). A PRV is a tradable voucher granted by the USFDA to encourage the development of new treatments for rare pediatric diseases, that can be redeemed to receive a priority review for a subsequent, separate drug application. The company intends to utilize the voucher to further accelerate its pipeline.

Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.

Sun Pharma Adv. Res Share Price

124.20 0.15 (0.12%)
06-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 399.15
Indegene 459.35
CMS Info Systems 300.35
JITF Infralogistics 355.50
Sagility 39.22
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×